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Evaluation of outcomes for psychosis 
and epilepsy treatment delivered by primary 
health care workers in Nepal: a cohort study
M. J. D. Jordans1,2, L. Aldridge1, N. P. Luitel3*, F. Baingana4 and B. A. Kohrt3,5
Abstract 
Background: Most evaluations of task-shifting have focused on common mental disorders. Much less work has 
been done on severe mental neurological and substance use (MNS) disorders, such as chronic psychosis and epilepsy. 
Given the high burden associated with severe MNS and the lack of mental health professionals in low and middle 
income countries, evaluations on the impact of task-shifting for these disorders are important.
Methods: In a rural district of Nepal, a community mental health program, based on World Health Organization’s 
Mental Health Gap Action Programme guidelines, was evaluated using a cohort study design. People with epilepsy 
and psychotic disorders were interviewed at treatment initiation and at 12-month follow-up. We also compared a 
group that was offered a comprehensive package of care (medication combined with psychosocial interventions, 
such as counselling and peer support groups) to a group that received medication only.
Results: One-hundred nineteen persons were enrolled in the epilepsy cohort (EC) and 85 in the psychosis cohort 
(PC). The patients were enrolled in either the comprehensive package (n = 157) or medication only (n = 47). There 
was significant improvement (P < 0.0001) in psychosis symptoms (PC: Z = 6.78, r = 0.80) and depressive symptoms 
(EC: Z = 7.43, r = 0.73; PC: Z = 6.02, r = 0.70), seizures (EC: Z = 6.78), functional disability (EC: Z = 6.38, r = 0.67; PC: 
Z = 4.60, r = 0.57), family and caregiver burden (EC: Z = 8.09, r = 0.85; PC: Z = 6.81, r = 0.84), and social behaviour 
(PC: Z = 5.94, r = 0.84). There was greater risk reduction for recent seizures among people with epilepsy in the com-
prehensive treatment package vs. medication only (risk ratio = 0.52, 95% CI 0.29–0.95; P = 0.03); no other signifi-
cant differences were observed between treatment arms.
Conclusions: A community mental health program in Nepal, implemented by non-specialists, resulted in moder-
ate to large effects among people with epilepsy or psychosis. A comprehensive package of care, including counsel-
ling and patient support groups, appears to offer added clinical benefits for patients with epilepsy. For people with 
psychosis, the basic package of care (i.e., psychotropic medications) performed similar to the comprehensive package, 
suggesting a less resource-intensive package may offer comparable results.
Keywords: Evaluation, Community mental health, Primary health care, Psychosis, Epilepsy, low and middle income 
country, Nepal
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Background
In most low- and middle income countries (LMIC) 
decentralized mental health services often range from 
inadequate to nonexistent [1], which is particularly 
concerning in light of the high burden of disease associ-
ated with mental illness globally [2]. Prior research has 
demonstrated high levels of common mental disorders in 
rural Nepal [3, 4], and a treatment gap (i.e. the percent-
age of people with mental illness that are not receiving 
adequate services) between 94.9 and 91.9 for alcohol use 
disorder and depression, respectively (Luitel et al., under 
review). Similar data on severe mental, neurological and 
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substance use (MNS) disorders are lacking for Nepal. 
The integration of mental health services within pri-
mary health care has long been advocated as a strategy to 
reduce the treatment gap, most recently through a set of 
clinical guidelines for health workers [5].
Consistent with this approach, the Mental Health 
Beyond Facilities (mhBeF) project aimed to establish a 
community-based mental health care program designed 
to reduce the treatment gap and relieve the clinical and 
social burden of severe MNS disorders for patients and 
their families. Patients enrolled in mhBeF receive a Men-
tal Health Care Package (MHCP) developed in accord-
ance with the World Health Organization’s (WHO) 
Mental Health Gap Action Programme (mhGAP; [6]), 
which relies on non-specialist health workers in primary 
care centers as the focal point for the detection and treat-
ment of mental disorders. The MHCP integrates both 
mental health services into primary health care, which 
pivots from a facility-based to a community-centric 
model of treatment, and is comprised of (i) strengthen-
ing clinical recognition, referral, assessment and man-
agement by non-specialist health care workers and (ii) 
community level activities such as case detection, family 
counselling and patient support groups (PSGs).
The present study evaluates the outcomes of a treat-
ment package for a cohort of patients with two MNS 
disorders, either psychosis or epilepsy, in rural Nepal. 
The primary objective is to evaluate the clinical and 
functional outcomes of the full cohort after 12  months 
of treatment. The secondary objective is to assess the 
added value of a comprehensive package of services over 
a minimal package of services. Ultimately the study aims 
to establish an evidence base for the viability of using this 
treatment model in Nepal and the potential for assimila-
tion into the Nepal healthcare system at scale.
Methods
Setting
The mhBeF program in Nepal was implemented in Pyu-
than district between 2013 and 2015. Pyuthan is a district 
located in the mid hills of the Rapti zone in the mid-
western development region of Nepal. Nepal ranks 145 of 
187 countries on the human development index (HDI) in 
2015. The objective of mhBeF was to develop and imple-
ment a comprehensive community-based mental health 
care plan, in accordance with the mhGAP guidelines, 
for persons with severe mental disorders (psychosis and 
bipolar disorder) and epilepsy in Liberia, Uganda, and 
Nepal [7].
Intervention arms
The study evaluated patients that were offered a com-
prehensive care package, which included; (a) clinical 
assessment and psychotropic treatment by primary 
health care (PHC) workers following the mhGAP Inter-
vention Guide (after receiving a 9-day training); (b) 
psychosocial support through individual or family coun-
selling and patient support groups (PSGs) by community 
counsellors (after receiving a 21-day training, in addi-
tion to a base training in counselling); and (c) conducting 
stigma reduction activities and ensuring follow-up care 
through home-based care by female community health 
volunteers (after receiving a 3-day training). Supervi-
sion of PHC workers by a psychiatrist was an integral 
component of the program. In addition the program 
used a newly developed procedure (Community Inform-
ant Detection Tool—CIDT) for pro-active case finding 
by community members to increase demand for mental 
health services. The CIDT has been developed in Nepal, 
and evaluated for accuracy [8] and impact on increased 
help seeking [9]. One group of the study participants 
was offered this comprehensive package of care, while a 
comparison group was offered a more basic set of ser-
vices consisting only psychotropic medicines (enhanced 
Treatment As Usual, eTAU) by mhGAP trained health 
workers, to allow the assessment of the added value of a 
comprehensive package of services over a minimal pack-
age of services. While the program planned to cater for 
people with psychosis, epilepsy and bipolar disorder, dur-
ing the implementation phase only 6 people with bipo-
lar were identified and treated. These people have been 
excluded from the study. Allocation to treatment or 
control arms was done by health facilities, which were 
geographically separated to minimize contamination. 
In the treatment arm we included the health facilities of 
12 Village Development Committees (VDC; the small-
est administrative unit in Nepal), and health facilities of 
5 VDCs were included in the control arm. We first listed 
all eligible VDCs within the district (excluding those 
where referral and supervision were not going to be fea-
sible). Next, we separated the health facilities (n = 5) that 
had received some form of prior mental health training 
(which was less than the training that was given as part of 
this study) from those that had never received such train-
ing. The former were allocated to the eTAU arm. Among 
the latter we randomly selected 12 health facilities—the 
number was set by the maximum capacity for project 
implementation.
Sample
Patients with a primary diagnosis of psychosis or epi-
lepsy established by PHC workers trained in mhGAP 
were recruited into a controlled cohort study. Inclu-
sion into the study followed a three-staged process. First 
potential respondents were identified as possibly having 
one of the target disorders (i.e. psychoses and epilepsy) 
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using the CIDT—as described above. Second, all identi-
fied individuals were screened using a brief screening 
instrument developed for the purpose. Third, if a person 
is found positive on one or more of the target disorders 
based on the screening procedure, he or she was assessed 
by trained PHC workers following the mhGAP guidelines 
for on the target disorders.
Procedures
All research assistants were selected from Pyuthan 
district and received a 3-week training. The training 
included basic communication and interviewing skills, 
research concepts and ethics, as well supervised practice 
of administering the surveys. Written consent was sought 
from all respondents, after a full explanation of the 
study. All individuals that were diagnosed and provided 
informed consent, baseline measurement was admin-
istered by research assistants. Recruitment took place 
between June 2014 and May 2015. Ethical approval for 
this study was obtained from the Nepal Health Research 
Council (NHRC) (Ref: 874; Reg 173/2013). Adverse 
events were monitored and responded to following TPO 
Nepal’s Adverse Events Reporting Procedure.
Measures
We selected a clinically-appropriate measure to assess 
symptom reduction for each disorder [1] Psychosis symp-
toms: people with psychosis completed the positive and 
negative symptoms scale (PANSS) (10), which has previ-
ously been validated in South Asia [11]. For this study we 
did not use the PANSS general scale, but only the positive 
and negative symptoms sub-scales (and for analyses com-
bined positive and negative symptoms sub-scales) [2]. 
Depression symptoms: all participants also completed 
the Hamilton Depression Scale (HAM-D; [12]), which we 
included due to the increased risk of depression among 
people with epilepsy and psychosis [3]. Seizures: For peo-
ple with epilepsy, a 9-item instrument to measure the 
number epileptic seizures in the previous 3 months (i.e., 
recent seizure) was used [13], which was scored dichoto-
mously [4]. Disability: we measured functional disability 
for all patients through the 12-item version of the WHO 
Disability Assessment Schedule 2.0 (WHODAS). The 
WHODAS has been used extensively and validated in 
many low- and middle-income countries [14], includ-
ing in Nepal [15]. We used the complex scoring method 
when calculating patients’ scores, which incorporates 
item weights [5]. Burden associated with mental illness, 
an important impact factor for caregivers and families 
of those with severe disorders, was measured through 
the burden assessment schedule (BAS; [16]) and two 
sections of the family interview schedule (FIS; [17]): 
symptoms and social behavior (FIS-SSB) and impact on 
caregiver (FIS-IC). The disability and burden measures 
were administered through family interview conducted 
by trained research assistants.
Translation of these instruments followed a stand-
ardized five-step procedure for translation of instru-
ments for use in transcultural research [18]. The PANSS, 
HAM-D, and Epilepsy-9 were administered by trained 
clinicians. The other instruments were administered by 
trained research assistants.
The primary outcomes for the study were the two dis-
order-specific clinical outcomes (i.e., PANSS score for 
psychosis and recent seizure for epilepsy) and associ-
ated functional impairment (i.e., WHODAS score). All 
other domains are considered secondary outcomes. Each 
measure was administered at baseline and at 12 months 
follow-up.
Analysis
We compared baseline characteristics of the study arms 
using χ2 tests for categorical data and an independent 
samples t-test for the single sample characteristic with 
continuous data, age of patient. To evaluate each clinical 
and functional outcome for the full cohort, we conducted 
a paired T-test for scaled outcomes, which compared 
baseline and endpoint scores on each measure for all 
patients. We evaluated the disorder-specific clinical out-
come for epilepsy (i.e. recent seizures), using McNemar’s 
exact χ2 for binomial paired data, which compared the 
proportion of patients with a recent seizure at baseline to 
that at endpoint. Analyses were carried out on a per pro-
tocol basis.
Differences in clinical and functional outcomes across 
treatment arms were assessed using an analysis of covari-
ance for each outcome. We set the treatment group as 
a fixed-effect exposure and baseline score as a covari-
ate, with the patient’s score at endpoint as the outcome. 
For measures that did not meet Levene’s test for equal-
ity of variance, we used a logarithmic transformation to 
account for heteroscedasticity [19]. We compared the 
reduction in risk of the dichotomous outcome for epi-
lepsy seizure across treatment arms through logistic 
regression. Again, treatment arm was set as a fixed-effect 
exposure and recent seizure at baseline as covariate, with 
recent seizure at endpoint as the outcome.
Upon reviewing the data for the cohort, there were 
outliers in the distribution of change scores for multiple 
scaled measures, indicating the possibility of an under-
lying non-normal distribution of outcomes. We deter-
mined post hoc to use the nonparametric equivalent 
of the paired T-test, the Wilcoxon Signed-Rank Test, 
when comparing baseline and end point scores for each 
measure. It was not necessary to select a nonparametric 
method for analysis between treatment arms despite the 
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presence of outliers since ANCOVA has demonstrated to 
be robust against violations of non-normality [20].
Results
Of the 204 patients enrolled at baseline, 85 (42%) and 
119 (58%) patients had a primary diagnosis of psycho-
sis and epilepsy, respectively. One hundred fifty-seven 
(77%) patients were included in the program arm (i.e., 
comprehensive services package; 63 with psychosis and 
94 with epilepsy) and 47 (23%) patients to the control 
arm (i.e., minimal services package; 22 with psycho-
sis and 25 with epilepsy). The majority of patients were 
married (64%), Hindu (99%), and did not attend second-
ary school (72%); approximately half of the patients were 
male (51%) and worked in agriculture (47%). One hun-
dred seventy-nine (88%) patients completed the clinician 
interviews at end point, while complete data from family 
interviews were available for 156 (76%). Table 1 presents 
the full distribution of sociodemographic characteristics 
for the sample.
The Signed-rank tests provide very strong evidence 
the cohort made significant improvements in all clini-
cal, functional, and burden-related outcomes. Patients 
with psychosis made significant improvements in psy-
chotic (Z  =  6.78, r  =  0.80) and depressive (Z  =  6.02, 
r  =  0.70) symptoms, functional impairment (Z  =  4.60, 
r = 0.57), familial burden (BAS: Z = 6.81, r = 0.84; FIS-
IC: Z =  5.13, r =  0.64), and social behavior (Z =  5.94, 
r = 0.84); all measures P < 0.0001. See Tables 2 and 3.
The Chi squared test for paired binomial data indi-
cated very strong evidence for a reduction in the risk 
of recent seizure at end point compared to baseline for 
patients with epilepsy (relative risk = 0.33, 95% CI 0.24–
0.45; P  <  0.0001). Patients with epilepsy also demon-
strated significant improvements in depressive symptoms 
(Z =  7.43, r =  0.73), functional impairment (Z =  6.38, 
r = 0.67), and familial burden (BAS: Z = 8.09, r = 0.85); 
all measures P < 0.0001. See Tables 4 and 5.
We found no evidence of significant differences in end-
point scores, adjusted for baseline scores, for clinical or 
Table 1 Sociodemographic characteristics of sample presented by total and subgroup percentages
a Average age presented as values, not percentages; also T-test p value presented for age comparison
eTAU enhance treatment as usual
Comprehensive treatment package (%) eTAU (%) Total (%) χ2 P value 
comparisonn = 157 n = 47 n = 204
Disorder 0.42
 Psychosis 40 47 42
 Epilepsy 60 53 58
Male 51 51 51 0.99
Average  agea 36.5 (14.4) 34.9 (11.5) 36.2 (13.8) 0.49
Highest level of education
 No formal education 38 43 39
 Primary level 32 34 33
 Secondary level 21 19 21
 Higher secondary or above 9 4 8
Employment category
 Unemployed 22 26 23
 Student or informal 11 43 19
 Agriculture 54 23 47
 Formal or day work 13 9 12
Caste 0.33
 Brahmin/Chhetri 34 23 32
 Dalit 30 32 30
 Janajati/Yogi/Puri/Giri 36 45 38
Married 61 74 64 0.08
Family income sufficient to sustain yourself? (months per year) 0.26
 A little (1–3) 10 17 12
 A quite bit (3–6) 29 34 30
 Very much (6–9) 33 34 33
 Always (9–12) 27 15 25
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Table 2 Clinical outcome summary scores from clinician interview for patients with psychosis
HAM-D Hamilton Depression Scale, PANSS positive and negative syndrome scale
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)
Program (n = 53) Control (n = 21) ANCOVA Full cohort (n = 74)
Mean SD Mean (SD) Effect size
F, partial  eta2
P-value* Mean (SD) Effect size
Z, r
P-value**
PANSS positive and negative < 0.01, < 0.01 0.96 6.87, 0.80 < 0.0001
Baseline 25.5 12.1 24.9 11.9 25.3 − 12
end point 7.9 7.4 10.3 12.2 8.6 − 9
Δ score − 17.6 12.5 − 14.6 14.1 − 16.8 − 12.9
PANSS positive 1.22, 0.02 0.22 6.87, 0.80 < 0.0001
Baseline 11.6 6.8 13.1 5.7 12 6.5
end point 2.7 3.3 3.7 4.6 3 4.6
Δ score − 8.9 7.7 − 9.3 7.5 − 9 7.5
PANSS negative 2.16, 0.03 0.69 6.42, 0.75 < 0.0001
Baseline 13.9 7.3 11.8 7.4 13.3 7.4
end point 5.2 5.3 6.6 7.7 5.6 6.1
Δ score − 8.7 7 − 5.2 8 − 7.7 7.4
HAM-D 0.02, < 0.01 0.27 6.02, 0.70 < 0.0001
Baseline 15.6 7.2 16.3 7.8 15.8 7.3
end point 7.7 4.5 8.0 6.7 7.8 6.7
Δ score − 7.8 8.0 − 8.4 11.3 − 8.0 9.0
Table 3 Functional and familial burden for psychosis
WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule, FIS Family Interview Schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)
Program (n = 48) Control (n = 17) ANCOVA Full cohort T
Mean (SD) Mean (SD) Effect size
F, partial  eta2
P-val* Mean (SD) Effect Size
Z, r
P-val**
WHODAS 0.52, 0.01 0.52 4.60, 0.57 < 0.0001
Baseline 46.1 (24.2) 37.4 (25.6) 43.8 (24.7)
end point 23.1 (20.8) 27.1 (30.9) 24.1 (23.7)
Δ score − 23.0 (27.0) − 10.3 (44.3) − 19.7 (32.6)
BAS 0.29, < 0.01 0.59 6.81, 0.84 < 0.0001
Baseline 76.5 (8.0) 76.0 (8.2) 76.4 (8.0)
end point 63.3 (6.5) 62.1 (9.3) 62.9 (7.3)
Δ score − 13.3 (8.6) − 13.9 (11.5) − 13.4 (9.4)
FIS: symptoms and social behavior 0.16, < 0.01 0.69 5.94, 0.74 < 0.0001
Baseline 46.5 (9.7) 41.2 (11.4) 45.1 (10.4)
end point 31.1 (9.4) 31.6 (11.0) 31.2 (9.8)
Δ Score − 15.4 (12.3) − 9.6 (15.8) − 13.9 (13.4)
FIS: impact on caregiver 2.02, 0.03 0.16 5.13, 0.64 < 0.0001
Baseline 12.0 (5.9) 10.9 (6.3) 11.7 (6.0)
end point 5.9 (4.3) 7.6 (5.7) 6.3 (4.7)
Δ score − 6.1 (6.4) − 3.3 (7.9) − 5.4 (6.9)
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functional outcomes across treatment arms (P > 0.15 for all 
measures), except the clinical outcome for epilepsy which 
indicated a greater reduction in recent seizure between 
within the comprehensive treatment arm (P  =  0.03). 
Patients with epilepsy in the comprehensive arm had only 
0.52 (95% CI 0.29–0.95) the risk of patients in the medica-
tion-only arm at end point after adjusting for recent sei-
zure at baseline (P = 0.03). See Tables 2, 3, 4 and 5.
When reviewing for changes in functioning and famil-
ial burden for the combined psychosis and epilepsy 
cohorts, we found significant improvements in functional 
impairment (Z =  7.83, r =  0.63), familial burden (BAS: 
Z = 10.56, r = 0.85), and no significant differences when 
comparing the treatment arms. See Table 6.
Discussion
The present study evaluates patient-level outcomes of a 
mhGAP-based mental health care package for people 
with psychosis and epilepsy in rural Nepal. The findings 
provide strong evidence that the cohort achieved sub-
stantial gains in every domain after 12 months of treat-
ment, including: psychotic symptoms, seizure frequency, 
and depressive symptoms; functional impairment; bur-
den for the caregiver and family; and social behavior. This 
means that primary health care workers, after receiving 
a brief training, are providing mental health care leading 
to significant improvements among participants. This is 
especially salient given the fact that the health workers in 
rural Nepal are all paramedics.
Table 4 Clinical outcome summary scores from clinician interview for patients with epilepsy
HAM-D Hamilton Depression Scale, CI confidence interval
* Wald test statistic p-value from logistic regression model comparing Program to Control outcomes, adjusted for seizure at baseline
** McNemar’s Exact χ2 test for binomial paired data: comparing baseline to end point proportion of clinical outcome (i.e., recent attack) for the full cohort
*** P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
**** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)
Seizures Program (n = 83) Control (n = 22) Study arm comparison Full cohort (n = 105)
n % 95% CI n % 95% CI RR (95% CI) P-value* n % 95% CI RR (95% CI) P-value**
Recent 0.52 (0.29–0.95) 0.03 0.33 (0.24–0.45) < 0.0001
Baseline 68 82 (72–90) 20 91 (71–99) 88 84 (75–90)
end point 19 23 (14–33) 10 45 (24–68) 29 28 (19–37)
HAM-D Mean SD Mean SD Effect size
F, partial  eta2
P-value*** Mean SD Effect size
Z, r
P-value****
Baseline 10.9 6.2 10.0 6.4 1.62, 0.02 0.21 10.7 6.2 7.43, 0.73 > 0.0001
end point 4.5 3.3 5.6 5.7 4.8 3.9
Δ score − 6.4 6.2 − 4.4 6.2 − 5.9 6.3
Table 5 Functioning and familial burden for epilepsy
WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)
Program (n = 71) Control (n = 20) ANCOVA Full cohort (n = 91)
Mean (SD) Mean (SD) Effect size
F, partial  eta2
P-val* Mean (SD) Effect size
Z, r
P-val**
WHODAS 0.72, < 0.01 0.40 6.38, 0.67 < 0.0001
Baseline 35.6 (20.9) 25.8 (21.3) 33.5 (21.3)
end point 10.2 (21.1) 12.8 (25.7) 10.8 (22.1)
Δ score − 25.4 (28.4) − 13.1 (21.7) − 22.7 (27.4)
BAS < 0.01, < 0.01 0.98 8.09, 0.85 < 0.0001
Baseline 73.0 (7.9) 69.1 (9.0) 72.1 (8.3)
end point 58.4 (6.6) 57.6 (6.4) 58.2 6.5
Δ score − 14.6 (9.0) − 11.5 (8.6) − 13.9 (8.9)
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We also compared subgroups within the cohort, 
namely those that received the comprehensive MHCP 
consisting of multiple community and facility-level inter-
ventions versus a minimal package (eTAU) consisting 
only of training of health workers and supply of psycho-
tropic medicines. The limitation of sample size inhibits 
our ability to make definitive interpretations of findings. 
Still, nearly all analyses suggest no difference in outcomes 
across treatment arms for all domains, with one excep-
tion: patients with epilepsy in receiving the comprehen-
sive MHCP had improved clinical outcomes (i.e., fewer 
seizures) compared to those receiving the basic MHCP. 
We did not evaluate the impact of the added components 
on treatment maintenance and adherence.
This finding suggests that for treating patients with 
epilepsy extra investment should be made in a treat-
ment package that includes medication as well as coun-
selling, patient support groups and stigma reduction 
interventions. This should be further evaluated through 
cost-effectiveness research, in order to assess whether it 
is worth the additional investments. For any other out-
comes, there is no additional gain for an elaborated offer 
of services compared to training and supply of medica-
tion only.
Limitations
The primary limitation of our analyses is a small sample 
size. The final sample size after attrition and exclusion 
of patients with missing data was n = 179 for measures 
administered through clinician interview, and fewer for 
those administered through family interviews. This limi-
tation is common to studies in low-resource settings; 
moreover, a relatively small sample size is a hallmark of 
cohort studies. The findings for primary objectives are 
not substantially affected by the sample size. It is in the 
comparisons of secondary objectives where the small 
sample size affects our ability to conduct subgroup 
analyses and will further limit findings should addi-
tional inferential analyses be conducted. Future research 
may consider testing specific hypotheses in addition 
to those presented here. For example, how might treat-
ment adherence affect disorder-specific outcomes, or are 
beliefs regarding the cause of psychosis associated with 
improvements in familial burden and functional impair-
ment? Finally, as a result of the absence of a control group 
that received no treatment at all (deemed unethical in the 
context of this study), we cannot empirically attribute 
change to the treatment. However, given the chronicity 
of the epileptic and psychotic symptoms, and the strong 
effects found, it is highly plausible that treatment has 
contributed to such change.
Conclusions
The findings provide strong evidence for clinical improve-
ments following mental health care delivered by primary 
health care workers—even paramedic staff—in treating 
epilepsy and psychosis. The study also shows the effect 
of that treatment in symptoms of depression, functional 
impairment and feelings of burden among family mem-
bers. A more comprehensive package of care, includ-
ing counselling and patient support groups, appears to 
offer added clinical benefits for patients with epilepsy. 
This entails that investments for additional psychosocial 
services beyond the chiefly pharmacological treatment 
provided by the health workers translate in significantly 
better treatment results. At the same time, for people 
with psychosis the basic package of care (i.e., psycho-
tropic medications) performed similar to the more com-
prehensive package, suggesting a less resource-intensive 
package may offer comparable results. In conclusion, our 
Table 6 Functional impairment combined for epilepsy and psychosis
WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)
Program Control ANCOVA Full cohort (n = 156) T
Mean (SD) Mean (SD) Effect size
F, partial  eta2
P-val* Mean (SD) Effect size
Z, r
P-val**
WHODAS 1.78, 0.01 0.18 7.83, 0.63 < 0.0001
Baseline 39.9 (22.8) 31.2 (23.8) 37.8 (23.2)
end point 15.4 (21.8) 19.4 (28.7) 16.3 (23.6)
Δ score − 24.5 (27.8) − 11.8 (33.5) − 21.5 (29.6)
BAS 0.01, < 0.01 0.92 10.56, 0.85 < 0.0001
Baseline 74.4 (8.1) 72.2 (9.2) 73.9 (8.4)
end point 60.4 (6.9) 59.6 (8.1) 60.2 (7.2)
Δ score − 14.0 (8.8) − 12.6 (10.0) − 13.7 (9.1)
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findings demonstrate the ability of this treatment model 
to significantly improve the lives of those with MNS dis-
orders and those their families. These findings also dem-
onstrate the viable of a scalable, integrated treatment 
model, which, if adopted into the wider healthcare sys-
tem, could dramatically expand access to mental health 
care for people with MNS disorder in Nepal.
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